AstraZeneca plc Stock
€139.45
Your prediction
AstraZeneca plc Stock
Pros and Cons of AstraZeneca plc in the next few years
Pros
Cons
Performance of AstraZeneca plc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
AstraZeneca plc | -0.610% | -0.853% | -11.037% | 7.850% | 14.116% | 39.199% | 68.540% |
GSK plc | 0.460% | 0.573% | -6.234% | 4.795% | 9.934% | 12.348% | -4.839% |
Elanco Animal Health Inc. | 4.060% | 1.762% | -1.339% | 19.182% | -5.148% | -54.298% | - |
Johnson & Johnson | 0.470% | -1.646% | -0.769% | -3.356% | 2.105% | 3.656% | 23.005% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Based on the financial statements of AstraZeneca, a pharmaceutical company with the US symbol AZNCF, the company appears to have experienced some growth and stability in recent years. However, there are still a few areas of concern among some positive trends. To fully understand the financial health of AstraZeneca, it is essential to conduct a detailed analysis of the company's financial statements, focusing on key financial metrics, pros, and cons.
Revenue growth: AstraZeneca's total revenue has been consistently growing in recent years, as indicated by the increase from 26.62 billion EUR in 2020 to 37.42 billion EUR in 2021 and 44.35 billion USD in 2022. This demonstrates a positive trend in sales and business performance.
Stable net income: Compared to 2021, AstraZeneca registered a significant improvement in net income, which stabilized at 3.29 billion USD in 2022. The consistent net income indicates that the company can meet its financial obligations, invest in new opportunities, and maintain profitability.
Comments